5,6,9,10,11,12-hexahydro-4H,8H-cyclohepta<4,5>pyrrolo<3,2,1-ij>quinoline | 65039-87-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5,6,9,10,11,12-hexahydro-4H,8H-cyclohepta<4,5>pyrrolo<3,2,1-ij>quinoline
• 英文别名: 5,6,9,10,11,12-hexahydro-4H,8H-cyclohepta[4,5]pyrrolo[3,2,1-ij]quinoline；4H,8H-5,6,9,10,11,12-hexahydrocyclohepta-[4,5]-pyrrolo-[3,2,1-ij]-quinoline；1-azatetracyclo[7.7.1.02,8.013,17]heptadeca-2(8),9,11,13(17)-tetraene
• CAS: 65039-87-4
• 化学式: C₁₆H₁₉N
• 分子量: 225.334
• InChiKey: YQZOPHCSKKZTCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  4.9
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  5,6,9,10,11,12-hexahydro-4H,8H-cyclohepta<4,5>pyrrolo<3,2,1-ij>quinoline 生成 4-methyl-N-[(2R,7R,8E)-8-(4-methylphenyl)sulfonylimino-9-azatetracyclo[7.7.1.02,7.013,17]heptadeca-1(16),13(17),14-trien-2-yl]benzenesulfonamide
  参考文献：
  名称：

  BAHADUR G. A.; BAILEY A. S.; BALDRY P. A., J. CHEM. SOC. PERKIN TRANS., PART 1, , 1977, NO 14, 1619-1626

  摘要：

  DOI：
• 作为产物：
  描述：

  C₂₁H₃₁N₃O₂ 在 Amberlyst 15H (dry form) 作用下， 以 甲醇 、 水 、 丙酮 为溶剂， 反应 12.0h， 生成 5,6,9,10,11,12-hexahydro-4H,8H-cyclohepta<4,5>pyrrolo<3,2,1-ij>quinoline
  参考文献：
  名称：

  不含金属和氧化剂的取代和/或多环吲哚的结构：比斯勒和相关合成的有用替代品

  摘要：

  通过使用1,2-二氮杂-1,3-二烯和苯胺的Amberlyst 15H催化合成，可以轻松组装各种取代的吲哚，包括复杂的多环结构。本文提出的无金属和氧化剂的方法的特点是产率高，总的和可预测的区域选择性以及提供吸电子取代的吲哚的能力。

  DOI：

  10.1002/ejoc.202000845

文献信息

• New anellated indole derivatives
  申请人：Duphar International Research B.V.

  公开号：US04939136A1

  公开（公告）日：1990-07-03

  The invention relates to new anellated indole derivatives of general formula 2, ##STR1## wherein p1 R.sub.0 is alkyl or alkoxy having 1-4 C-atoms, phenylalkoxy having 1-3 C-atoms in the alkoxy group, hydroxy, halogen, trifluoromethyl, trifluoromethoxy, trifluoromethylthio, or a group R.sub.7 S(O).sub.p, wherein R.sub.7 is alkyl having 1-4 C-atoms and p has the value 0, 1 or 2, or R.sub.0 is a group R.sub.8 R.sub.9 N, R.sub.8 R.sub.9 N--CO--CH.sub.2 -- or R.sub.8 R.sub.9 --N--CO wherein R.sub.8 and R.sub.9 are hydrogen or alkyl having 1-4 C-atoms or R.sub.8 R.sub.9 N forms a saturated 5- or 6-membered ring and n has the value 0, 1 or 2, Z together with the carbon atom and nitrogen atom to which Z is bound and the intermediate carbon atom, forms a heterocyclic group consisting of 5-8 ring atoms, in which, in addition to the nitrogen atom already present, a --CO--group or a second hetero atom from the group N, O, S, S-O or SO.sub.2 may be present, which ring may be substituted with 1-3 alkyl groups having 1-4 C-atoms, a phenyl group or a spiroalkyl group (C.sub.2 -C.sub.5), or which ring may be anellated with a saturated or non-saturated carbocyclic or heterocyclic ring which consists of 5- or 6-ring atoms and which may be substituted with halogen, alkyl or alkoxy having 1-4 C-atoms, and m has the values 1-5, one of the groups R.sub.2, R.sub.3 and R.sub.4 is hydrogen, alkyl having 1-6 C-atoms, cycloalkyl having 3-7 C-atoms, alkenyl having 2-6 C-atoms or phenylalkyl having 1-3 C-atoms in the alkyl group, and the two other groups independently of each other are hydrogen or alkyl having 1-6 C-atoms, and the pharmaceutically acceptable acid addition salts thereof. These compounds are strong and selective antagonists of "neuronal" 5-hydroxytryptamine (5-HT) receptors, and have a considerably longer-lasting effect and lower toxicity in comparison with related known compounds.

  该发明涉及一般式2的新的环化吲哚衍生物，其中p1 R.sub.0是具有1-4个碳原子的烷基或烷氧基，苯基烷氧基在烷氧基中具有1-3个碳原子，羟基，卤素，三氟甲基，三氟甲氧基，三氟甲硫基，或者一个基团R.sub.7 S(O).sub.p，其中R.sub.7是具有1-4个碳原子的烷基，p的值为0、1或2，或者R.sub.0是一个基团R.sub.8 R.sub.9 N，R.sub.8 R.sub.9 N--CO--CH.sub.2 --或R.sub.8 R.sub.9 --N--CO，其中R.sub.8和R.sub.9是氢或具有1-4个碳原子的烷基，或者R.sub.8 R.sub.9 N形成饱和的5-或6-成员环，n的值为0、1或2，Z与碳原子和氮原子一起形成一个由5-8个环原子组成的杂环基团，在该基团中，除了已经存在的氮原子外，还可能存在一个--CO--基团或来自N、O、S、S-O或SO.sub.2组的第二个杂原子，该环可能被1-3个具有1-4个碳原子的烷基、苯基或螺环烷基（C.sub.2 -C.sub.5）取代，或者该环可能与由5个或6个环原子组成的饱和或非饱和碳环或杂环环相连，该环可能被卤素、具有1-4个碳原子的烷基或烷氧基取代，m的值为1-5，R.sub.2、R.sub.3和R.sub.4中的一个是氢、具有1-6个碳原子的烷基、具有3-7个碳原子的环烷基、具有2-6个碳原子的烯基或者在烷基中具有1-3个碳原子的苯基烷基，另外两个基团独立地是氢或具有1-6个碳原子的烷基，以及其药用可接受的酸盐。这些化合物是“神经元”5-羟色胺（5-HT）受体的强效和选择性拮抗剂，与相关已知化合物相比，具有更持久的效果和更低的毒性。
• TETRACYCLIC INDOLES AS POTASSIUM CHANNEL MODULATORS
  申请人：WILSON Matthew A.

  公开号：US20080027090A1

  公开（公告）日：2008-01-31

  The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.

  本发明涉及以下的化合物：Formula I，它们是钾通道调节剂及其药物组合物。本发明还涉及使用这些化合物和药物组合物进行治疗的方法。本发明还涉及用于生产本发明化合物的合成过程。
• Tetracyclic indoles as potassium channel modulators
  申请人：Wyeth LLC

  公开号：US07662831B2

  公开（公告）日：2010-02-16

  The present invention is directed to compounds of Formula I: that are potassium channel modulators and pharmaceutical compositions thereof. The present invention is further directed to methods of treatment using the compounds and pharmaceutical compositions of the invention. The present invention is still further directed to synthetic processes for producing the compounds of the invention.

  本发明涉及一种公式I的化合物，该化合物是钾通道调节剂及其制药组合物。本发明还涉及使用该化合物和制药组合物的治疗方法。本发明还进一步涉及生产该化合物的合成过程。
• Letcher, Roy M.; Choi, Michael C.K.; Acheson, R.Morrin, Journal of the Chemical Society. Perkin transactions I, 1983, # 3, p. 515 - 526
  作者：Letcher, Roy M.、Choi, Michael C.K.、Acheson, R.Morrin

  DOI：——

  日期：——
• Letcher, Roy M.; Choi, Michael C. K., Journal of Chemical Research, Miniprint, 1988, # 5, p. 1262 - 1275
  作者：Letcher, Roy M.、Choi, Michael C. K.

  DOI：——

  日期：——